CKDXF
CKDXF clinical trials: Opthea Ltd
Every trial on ClinicalTrials.gov where Opthea Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CKDXF on the catalyst calendar · CKDXF registry changes
- Primary completion Mar 31, 2025ActualPhase 3NCT04757636OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)Opthea Limited · Neovascular Age-related Macular DegenerationTerminatedCKDXFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2025ActualPhase 3NCT04757610OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)Opthea Limited · Neovascular Age-related Macular DegenerationTerminatedCKDXFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2020ActualPhase 1/Phase 2NCT03397264A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular EdemaOpthea Limited · Diabetic Macular EdemaCompletedCKDXFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 14, 2019ActualPhase 2NCT03345082A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMDOpthea Limited · Neovascular Age-related Macular DegenerationCompletedCKDXFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 7, 2017ActualPhase 1NCT02543229Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMDOpthea Limited · Eye DiseasesCompletedCKDXFLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner